Twitter | Search | |
Search Refresh
ArrowheadPharma Jun 27
The FDA has granted to our subcutaneously administered therapeutic, ARO-AAT, for the treatment of a rare genetic liver disease associated with antitrypsin deficiency (AATD). See press release for details:
Reply Retweet Like
Biotech News 15 Jan 15
An inside look at the FDA's approach to speeding new drug approvals
Reply Retweet Like
AJPB_Journal 18 Sep 16
Reply Retweet Like
Debiopharm 8 May 18
Reply Retweet Like
InfectiousDiseaseAdv 9 May 18
Reply Retweet Like
Orbis Biosciences 9 Mar 17
FDA Grants OncoSec for Metastatic Melanoma Following Pembrolizumab/Nivolumab | Street Insider
Reply Retweet Like
Sandra Marticio 16 Nov 16
Reply Retweet Like
1stOncology Jun 6
Reply Retweet Like
1stOncology 1 Sep 17
Iovance Biotherapeutics Reports FDA for for Treatment of Advanced
Reply Retweet Like
quantumup Apr 13
Replying to @Quantumup1
When is the or coming, It's not a matter of if, it's a matter of when! This stock is so grossly undervalued, with the clinical data so robust.
Reply Retweet Like
Bosco May 14
How much is a from worth to ?
Reply Retweet Like
CBPartners 15 Sep 17
chronic treatment for premature infants receives
Reply Retweet Like
1stOncology 29 Apr 16
Reply Retweet Like
Samantha B Thompson 28 Nov 16
Reply Retweet Like
MDedge Hematology & Oncology 26 Apr 17
Reply Retweet Like
MDedge Hematology & Oncology 23 Sep 16
Reply Retweet Like
1stOncology Jun 19
Reply Retweet Like
1stOncology 12 May 15
Reply Retweet Like
Aegis Creative 26 Oct 16
gets for to treat explore what's going on w/ &
Reply Retweet Like
BioEnterprise Corp. May 20
Big congratulations to client company on receiving for its therapy for acute respiratory distress syndrome from the FDA
Reply Retweet Like